Long-Term Open Label Treatment of AD

† Weeks from the beginning of the double-blind study Friedhoff et al. Int J Neuropsychopharmacol 1999;2(Suppl 1):S175

ADAS-Cog Mean change from baseline (±SE)

Study week†

No. of

subjects: 133 124 100 56 46 37 34 28 25

–6

122

146

170

194

Aricept-treated patients

95% confidence interval

Clinical improvement

Clinical decline

Decline in ADAS-cog score (9–11 points

per year) based on the natural history of

untreated patients with moderate AD†